Group 1: Earnings Performance - Enovis reported quarterly earnings of $0.81 per share, exceeding the Zacks Consensus Estimate of $0.74 per share, and up from $0.50 per share a year ago, representing an earnings surprise of 9.46% [1] - The company posted revenues of $558.83 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.03%, and an increase from $516.27 million year-over-year [2] - Over the last four quarters, Enovis has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Enovis shares have declined approximately 22% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.74 for the coming quarter and $3.19 for the current fiscal year [4][7] - The current Zacks Rank for Enovis is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical Info Systems industry, to which Enovis belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Viewpoint - Cenovus Energy reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of $0.29 per share, but down from $0.46 per share a year ago, indicating a mixed performance in earnings despite a positive surprise this quarter [1][2]. Financial Performance - The company posted revenues of $9.26 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.18% and down from $9.94 billion year-over-year [2]. - Over the last four quarters, Cenovus has surpassed consensus EPS estimates only once, while topping revenue estimates two times [2]. Stock Performance - Cenovus shares have declined approximately 22.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3]. - The current Zacks Rank for Cenovus is 3 (Hold), indicating expected performance in line with the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $9.21 billion, and for the current fiscal year, it is $1.41 on revenues of $37.83 billion [7]. - The outlook for the industry, specifically the Oil and Gas - Integrated - Canadian sector, is currently in the top 24% of Zacks industries, suggesting a favorable environment for performance [8].

Lincoln National (LNC) came out with quarterly earnings of $1.60 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.90%. A quarter ago, it was expected that this insurance and retirement business would post earnings of $1.74 per share when it actually produced earnings of $1.91, delivering a surprise of 9.77%.Over the last fou ...

Group 1 - Millicom International Cellular SA (TIGO) reported quarterly earnings of $1.14 per share, exceeding the Zacks Consensus Estimate of $0.91 per share, and showing a significant increase from $0.54 per share a year ago, resulting in an earnings surprise of 25.27% [1] - The company posted revenues of $1.37 billion for the quarter ended March 2025, which was 3.81% below the Zacks Consensus Estimate and a decrease from $1.49 billion in the same quarter last year [2] - Millicom's shares have increased approximately 36% since the beginning of the year, contrasting with a decline of 4.3% in the S&P 500 [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Millicom is currently mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.89 on revenues of $1.44 billion, and for the current fiscal year, it is $3.10 on revenues of $5.75 billion [7] Group 3 - The Wireless Non-US industry, to which Millicom belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact the stock's performance [8]

分组1 - RxSight, Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.12 per share a year ago, representing a 25% earnings surprise [1] - The company posted revenues of $37.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.01%, and showing an increase from $29.51 million year-over-year [2] - RxSight has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has lost approximately 59.4% since the beginning of the year, compared to a decline of 4.7% in the S&P 500 [3] - The current consensus EPS estimate for the coming quarter is $0.01 on revenues of $42.48 million, with a breakeven estimate of $174.01 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Instruments is in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Viewpoint - Jackson Financial (JXN) reported quarterly earnings of $5.10 per share, exceeding the Zacks Consensus Estimate of $4.93 per share, and showing an increase from $4.23 per share a year ago, indicating a positive earnings surprise of 3.45% [1][2] Financial Performance - The company posted revenues of $1.77 billion for the quarter ended March 2025, which was slightly below the Zacks Consensus Estimate by 0.19%, and a decrease from $2.77 billion in the same quarter last year [2] - Over the last four quarters, Jackson Financial has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Jackson Financial shares have declined approximately 6.1% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The current Zacks Rank for Jackson Financial is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.66 on revenues of $1.73 billion, and for the current fiscal year, it is $18.87 on revenues of $6.89 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock performance [6] Industry Context - The Insurance - Life Insurance industry, to which Jackson Financial belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Group 1 - AerSale Corporation reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of $0.13, and compared to earnings of $0.11 per share a year ago, representing an earnings surprise of -138.46% [1] - The company posted revenues of $65.78 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 25.31%, and down from year-ago revenues of $90.54 million [2] - Over the last four quarters, AerSale has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Group 2 - AerSale shares have increased by approximately 11.8% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for AerSale is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $84.34 million, and for the current fiscal year, it is $0.70 on revenues of $368.49 million [7] - The Aerospace - Defense Equipment industry is currently ranked in the top 14% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Core Viewpoint - GoodRx Holdings, Inc. reported quarterly earnings of $0.09 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.08 per share a year ago [1] - The company posted revenues of $202.97 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 0.19% and up from $197.88 million year-over-year [2] Financial Performance - GoodRx's earnings have not surpassed consensus EPS estimates over the last four quarters [1] - The company has topped consensus revenue estimates only once in the past four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $205.65 million, and for the current fiscal year, it is $0.40 on revenues of $824.14 million [7] Market Performance - GoodRx shares have declined approximately 8.4% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical Services industry, to which GoodRx belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact GoodRx's stock performance [5]

Core Insights - Goodyear reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.06, compared to earnings of $0.10 per share a year ago, indicating an earnings surprise of 33.33% [1] - The company posted revenues of $4.25 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.37%, and down from $4.54 billion year-over-year [2] - Goodyear shares have increased by approximately 21.8% since the beginning of the year, contrasting with a decline of 4.7% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $4.5 billion, and for the current fiscal year, it is $1.45 on revenues of $18.48 billion [7] - The estimate revisions trend for Goodyear is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Rubber - Tires industry, to which Goodyear belongs, is currently in the top 9% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Nuvation Bio Inc. reported a quarterly loss of $0.16 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.07 per share a year ago [1] - The company generated revenues of $3.08 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 23.36%, while revenues were zero a year ago [2] - Nuvation Bio's shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] Earnings Outlook - The earnings outlook for Nuvation Bio is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $2.5 million, and for the current fiscal year at -$0.69 on revenues of $15 million [7] - The company's earnings outlook will significantly depend on management's commentary during the earnings call [2] Industry Context - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nuvation Bio's stock performance [5]